Attached files
| file | filename |
|---|---|
| 8-K - 8-K - T2 Biosystems, Inc. | a17-7857_18k.htm |
Exhibit 99.1
T2 Biosystems, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
|
|
|
Three Months Ended |
|
Twelve Months Ended |
| ||||||||
|
|
|
2016 |
|
2015 |
|
2016 |
|
2015 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Revenue: |
|
|
|
|
|
|
|
|
| ||||
|
Product revenue |
|
$ |
579 |
|
$ |
343 |
|
$ |
1,747 |
|
$ |
599 |
|
|
Research revenue |
|
331 |
|
668 |
|
2,333 |
|
2,214 |
| ||||
|
Total revenue |
|
910 |
|
1,011 |
|
4,080 |
|
2,813 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Costs and expenses: |
|
|
|
|
|
|
|
|
| ||||
|
Cost of product revenue |
|
2,171 |
|
910 |
|
6,872 |
|
1,740 |
| ||||
|
Research and development expenses |
|
5,851 |
|
6,638 |
|
24,009 |
|
25,362 |
| ||||
|
Selling, general and administrative expenses |
|
5,795 |
|
5,008 |
|
24,077 |
|
19,094 |
| ||||
|
Total costs and expenses |
|
13,817 |
|
12,556 |
|
54,958 |
|
46,196 |
| ||||
|
|
|
|
|
|
|
|
|
|
| ||||
|
Loss from operations |
|
(12,907 |
) |
(11,545 |
) |
(50,878 |
) |
(43,383 |
) | ||||
|
Interest expense, net |
|
(1,682 |
) |
(513 |
) |
(4,098 |
) |
(1,967 |
) | ||||
|
Other income, net |
|
40 |
|
26 |
|
172 |
|
60 |
| ||||
|
Net loss and comprehensive loss |
|
$ |
(14,549 |
) |
$ |
(12,032 |
) |
$ |
(54,804 |
) |
$ |
(45,290 |
) |
|
|
|
|
|
|
|
|
|
|
| ||||
|
Net loss per share - basic and diluted |
|
$ |
(0.48 |
) |
$ |
(0.56 |
) |
$ |
(2.11 |
) |
$ |
(2.21 |
) |
|
Weighted-average number of common shares used in computing net loss per share |
|
30,457,063 |
|
21,322,799 |
|
26,015,751 |
|
20,501,748 |
| ||||
T2 Biosystems, Inc.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
|
|
|
December 31, |
|
December 31, |
| ||
|
|
|
|
|
|
| ||
|
Assets |
|
|
|
|
| ||
|
Current Assets: |
|
|
|
|
| ||
|
Cash and cash equivalents |
|
$ |
73,488 |
|
$ |
73,662 |
|
|
Accounts receivable |
|
327 |
|
369 |
| ||
|
Prepaid expenses and other current assets |
|
820 |
|
838 |
| ||
|
Inventory, net |
|
803 |
|
683 |
| ||
|
Total current assets |
|
75,438 |
|
75,552 |
| ||
|
Property and equipment, net |
|
13,589 |
|
10,655 |
| ||
|
Restricted cash |
|
260 |
|
260 |
| ||
|
Other assets |
|
281 |
|
358 |
| ||
|
Total assets |
|
$ |
89,568 |
|
$ |
86,825 |
|
|
|
|
|
|
|
| ||
|
Liabilities and stockholders’ equity |
|
|
|
|
| ||
|
Current liabilities: |
|
|
|
|
| ||
|
Accounts payable |
|
$ |
962 |
|
$ |
1,228 |
|
|
Accrued expenses and other current liabilities |
|
4,908 |
|
4,162 |
| ||
|
Current portion of notes payable |
|
1,269 |
|
4,449 |
| ||
|
Current portion of lease incentives |
|
301 |
|
268 |
| ||
|
Deferred revenue |
|
2,445 |
|
2,146 |
| ||
|
Total current liabilities |
|
9,885 |
|
12,253 |
| ||
|
Notes payable, net of current portion |
|
39,504 |
|
26,121 |
| ||
|
Lease incentives, net of current portion |
|
792 |
|
1,076 |
| ||
|
Other liabilities |
|
49 |
|
436 |
| ||
|
Commitments and contingencies |
|
— |
|
— |
| ||
|
Stockholders’ equity: |
|
|
|
|
| ||
|
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2016 and December 31, 2015; 30,482,712 and 24,175,381 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively |
|
30 |
|
24 |
| ||
|
Additional paid-in capital |
|
242,997 |
|
195,800 |
| ||
|
Accumulated deficit |
|
(203,689 |
) |
(148,885 |
) | ||
|
Total stockholders’ equity |
|
39,338 |
|
46,939 |
| ||
|
Total liabilities and stockholders’ equity |
|
$ |
89,568 |
|
$ |
86,825 |
|